Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 200...(h of which were incurred during the firs...),Health

fiscal 2008, and an estimated $5.1 million, or $0.41 per share,

related to the sale of the Company's endovascular business during the

fourth quarter of fiscal year 2008. Diluted earnings per share for

the fourth quarter of fiscal year 2007 included an after-tax charge

for the discontinuance of the Company's embolic protection platform

of $3.1 million, or $0.25 per share.

Three Months Three Months Year over Year

Ended Ended % Change

September 30, 2008 September 30, 2007

Range Range

Low High Low High

Diluted Earnings Per

Share - GAAP $0.34 $0.36 $(0.02)

Special Charges (c) - - 0.17

Adjusted Diluted

Earnings Per Share $0.34 $0.36 $0.16 113% 125%

(c) Diluted earnings per share for fiscal year 2008 includes after-tax

charges of $2.0 million, or $0.16 per share, for the acceleration of

stock awards, approximately $214,000, or $0.02 per share, of charges

related to the discontinuation of the Company's embolic protection

platform, both of which were incurred during the first quarter of

fiscal 2008.

Twelve Months Twelve Months Year over Year

Ended Ended % Change

June 30, 2009 June 30, 2008

Range Range Range

Low High Low High Low High

Diluted Earnings Per

Share - GAAP
'/>"/>